USE OF MUTEINS OF WILD-TYPE CYTOKINES AS IMMUNOGENS

Abstract: These are pharmaceutical compounds used to treat or prevent diseases caused by the over-production of a specific wild-type cytokine, characterised by the fact that they contain as an active principle at least one mutant of that wild-type cytokine. In its widest scope the invention consists in the use of muteins of a specific wild-type cytokine, that are also receptor antagonists of the latter, as immunogens to elicit antibodies directed against this wild-type cytokine and capable of neutralising it in those diesases caused by its excessive production. Figure 4 shows that antibodies developed in NSE/hIL-6 transgenic mice immunised with a human interleukin 6 mutein are capable of recognising wild-type interleukin 6 and of neutralising its biological activity.

Description: USE OF MUTEINS OF WILD-TYPE CYTOKINES AS IMMUNOGENS DESCRIPTTON The present invention relates to the use of muteins of a specific wild-type cytokine, that are also receptor antagonists of the latter, as immunogens to elicit antibodies against the wild-type cytokine, said antibodies being capable of neutralising the biological activity of the wild-type cytokine in diseases caused by an excessive production of the latter. It is a known fact, for example, that human interleukin 6 (hIL-6) is a polypeptide of 184 aminoacids belonging to the class of helical cytokines. Interleukin 6 is a multi-functional cytokine produced by various cell types. It acts as a differentiation and growth factor on cells of various types, for example the cells of the immune system, hepatocytes, kidney cells, haematopoietic stam cells, keratinocytes and neurons. However, excessive production of hIL-6 is causes a number of diseases, such as chronic auto-immune disorders, systemic lupus erythematosus, myeloma/plasmacytoma, post- menopausal osteoporosis and cancer cachexy. There is thus a need in this specific sector to counteract the excessive production of a wild-type cytokine in general, and of hIL-6 in particular, both in terms of prevention and of cure. The use of the present invention enables this need to be satisfied, offering at the same time other advantages which will become clear from the following. A subject of the present invention is in fact the use of mutants of a wild-type cytokine for the preparation of pharmaceutical compounds for the treatment or prevention of diseases caused by an over-production of this specific wild-type cytokine. A further subject of the present invention are pharmaceutical compounds for treatment of diseases caused by the excessive production of a wild-type cytokine, or vaccines for the prevention of said diseases containing as an active principle at least one mutant of that wild- type cytokine. The pharmaceutical compounds according to the present invention may be formulated according to known methods, which requires for example the presence of a pharmaceutically acceptable vehicle. Examples of these vehicles and methods of formulation can be found in Remington's Pharmaceutical Sciences. To form a pharmaceutically acceptable compound suitable for effective admninistration, these compounds must contain an effective amount of the active principle according to the present invention. The pharmaceutical compounds of the present invention are administered to an individual in amounts adequate to the disease, the weight, the sex and the age of the individual in question. Other factors include the method of administration. The pharmaceutical compounds according to the invention may be administered in a wide range of manners, for example subcutaneously, topically, orally and by intramuscular injection. The pharmaceutical compounds according to the present invention, containing as an active ingredient at least one mutein of a wild-type cytokine, may be administered at therapeutic doses in a wide variety of forms, in conventional administration vehicles. For example, they can be administered in doses to be taken orally in the form of tablets, capsules, pills, powders, granules, elixirs, ointments, solutions, suspensions, syrups and emulsions, or by injection. In the same way, these compounds according to the invention may be administered endovenously, intraperitoneally, subcutaneously, topically with or without occlusion, or intramuscularly. All the above formes of dosage are well known to those skilled in the pharmaceutical field. In any case an effective, but non toxic amount of the active principle according to the invention must be used. The daily dose of this active principle may vary within a wide range of between 0.01 to 1000 mg per adult/per day. An effective amount of the active principle according to the invention is usually provided at a dosage of between approximately 0.001 mg/kg and approximately 100 mg/kg of body weight per day. According to the present invention, the active principle, which is made up of muteins of a specific wild-type cytokine, may be administered typically in a mixture with suitable diluents, excipients or pharmceutical vehicles (generally referred to by the general term "vehicles") suitably selected so as to bear in mind the form of administration desired. The preparation of vaccines according to the present invention is known to persons skilled in this field. Typically, these vaccines are prepared in an injectable form, either as solutions or as suspensions. The preparation can be emulsionated, or the active principle, can be incapsulated in lyposomes. The active immungenic ingredient is often mixed with pharmaceutically acceptable excipients that are compatible with the active ingredient. Suitable excipients are, for example, water, dextrose, glycerol, ethanol or the like and combinations thereof. Furthermore, if desired, the vaccine may contain small amounts of additional substances, such as, for example, wetting or emulsionating agents, pH buffering agents, and/or adjuvants to increase the effectiveness of the vaccine. The vaccines according to the invention are preferably administered parenterally, for example by means of either intramuscular or subcutaneous injection. Other formulations suitable for other methods of administration include- suppositories and oral formulations. These compounds contain from 10 to 95% of active ingredient, preferably between 25 and 70%. Up to this point a general description has been given of the present invention. With the aid of the following examples a more detailed description will now be given, indicating specific situations that can be referred to the present invention, and aimed at giving a clearer understanding of the aims, characteristics, advantages and possible applications thereof. Figures la and lb show the results of the experiment of immunisation of normal and NSE/hIL-6 transgenic mice with wild-type hIL-6. Figures 2a and 2b show the results of the experiment of immunisation with the mutant form, briefly indicated as Santl (containing the mutations Tyr 31 Asp, Gly 35 Phe, Ser 118 Arg, Val 121 Asp, Gin 175 Ile, Ser 176 Arg, Gin ' 183 Ala and being an antagonist of hIL-6) in normal and in NSE/hI -6 transgenic mice. Figure 3 shows the results of the experiment aimed at verifying whether or not the antobodies developed in mice against Santl are also capable of recognising wild- type IL-6. Figure 4 shows the results of the experiment aimed at verifying whether or not the antibodies developed in NSE/hIL-6 transgenic mice immunised with the wild-type interleukin 6 mutant Santl are capable of neutralising the biological activity of wild-type human interleukin 6. Figures 5a and 5b show the results of experiments carried out in example 7. Figures 6a and 6b show the results of experiments carried out in example 11. EXAMPLE 1 Tmπiimisat-.ion Ql NSE/hIL-6 tranπσenic mi C . wi h immune tol lerance for hIL-6. using hIL-6 and Santl The NSE/hIL-6 transgenic mice have integrated into their genome the cDNA of human interleukin 6, under the control of the rat neuro-specific enolase gene promote. The theory of tollerance was verified by attempting to immunize the above mentioned NSE/hIL-6 transgenic mice (a group of five mice) with recombinant human IL-6; as a control, siblings born in the same litter, but without the transgene were used. A group of five NSE/hIL-6 transgenic mice was also immunised with a mutant form of IL-6, called Santl (which does not have residual biological activity on human cells and behaves as an h-IL 6 receptor antagonist) , which contained the seven mutations indicated below: Tyr 31 Asp, Gly 35 Phe, Ser 118 Arg, Val 121 Asp, Gin 175 Ile, Ser 176 Arg, Gin 183 Ala. In this case also five siblings from the same litter but without the transgene were used as controls. The immunisation protocol was as follows: at time zero a sample of blood (pre-immune sample) was taken in sequence from each animal, both transgenic and non, and then each animal was immunised intraperitoneally (IP) with 100 μg of antigen (wt hIL-6 or Santl, according to the group of mice) in the presence of Complete Freund Adjuvant (CFA) . Ten days after the first immunization, a blood sample was taken (sample 1) . Twenty days after first immunization a second immunization was carried out (first booster) , again using 100 μg of antigen, in the presence of Incomplete Freund's Adjuvant (IFA) , followed ten days later (30 days from first immunization) by a second blood sample (sample 2) . Finally, fourty days after the first immunization a third immunization was carried out (second booster) again using 100 μg of antigen, in the presence of IFA, followed ten days later (50 days from first immunization) by the third blood sample (sample 3) . The corresponding serum was prepared from each of the blood samples, according to the state of the art. At this point the "ELISA" method (Enzyme Linked ImmunoSorbent Assay) was used to test whether or not antibodies directed against the antigen used for immunization were present in the serum obtained from the second and third samples. To do this, the same antigen used for immunization was bound in a non co-valent manner to the bottom of the wells in culture plates specially produced for this type of experiment (ELISA plates) . Immobilisation of the antigen took place by incubating 100 μl of a solution of antigen dissolved at 10 μl/ml in IX PBS for 14 hours at room temperature in each of the wells to be coated (an operation termed "coating") . After immobilisation of the antigen, the plastic in the wells was coated with proteins, incubating a solution of 0.8% BSA (Bovine Serum Albumin) in IX PBS for 4 hours at room temperature in each of the wells (an operation termed "blocking") . After removal of the "blocking" solution, 100 μl of each serum, suitably diluted, were incubated singly in each well for 90 minutes at room temperature: during this stage, if there are in the serum any antibodies for the antigen immobilised on the bottom of the well, these will bind the antigen itself, and will in turn be bound to the bottom of the well. After the 90 minute incubation period, the serums were removed from the wells and, after adequate washing, 100 μl of 0.8% BSA in 1XPBS containing rabbit antibodies directed against mouse antibodies were added to each well, and incubation was continued for 50 minutes at room temperature. During this stage, if mouse antibodies have recognised and bound the antigen immobilised on the bottom of the well, these mouse antibodies will be recognised and bound by the rabbit antibodies, which will thus in turn be immobilised on the bottom of the well. Furthermore, the rabbit antibodies directed against mouse antibodies (used diluted at a ratio of 1:100 in PBS/BSA for the above mentioned experiment) , which are produced and distributed by the company DAKO, are covalently linked to an enzyme, horseradish peroxidase. After the 50 minutes of incubation, the solution containing rabbit antibodies was removed, and the wells were adequately washed. At this point, 100 μl of a solution containing a substrate (TMB: 3, -3', -5, -5' -tetramethyl-benzydine-dichloride) for horseradish peroxidase were added to each well. The enzyme converts the substrate into a product that absorbs visible light at 450 nanometers; thus the amount of conversion can be calculated by spectrophotometric measurement of the light absorbtion at 450 nm in each single well, using an ELISA reader. If the experiment is carried out correctly, the absorbance (that is to say the amount of light absorbed) is proportional to the amount of enzyme, which is in turn proportional to the " amount of rabbit antibody, which is in turn proportional to the amount of mouse antibody directed against the antigen originally present in the serum. Thus, the measurement of the absorbance gives an estimate of the amount of mouse antibody directed against the antigen present in the serum. This is true if the mouse antibody against the antigen is the factor limiting the chain of reactions described above. Thus, to obtain the appropriate conditions, it is advisable to carry out a series of dilutions (from 1:33 to 1:8100) for each serum to be examined, so that, for each serum there will be certain dilutions in which the amount of mouse antibody for the antigen used for immunization will be sufficiently high to be measured with precision, but not so high as to saturate the system. The results of the wild-type IL-6 (wtIL-6) immunization experiment are illustrated in figures la and lb for a typical normal mouse and for a typical NSE/hIL-6 transgenic mouse. As can be seen from figure la, the normal mouse has developed a large amount of anti-wtIL-6 antibodies, so much so that it is possible to detect a signal even when the serum is diluted to 1:8100. Vice versa, as can be seen from figure lb, the transgenic mouse has developed a much lower amount of antibodies: in fact the signal ceases when the serum from the second sample is diluted at a ratio of 1:300 and when the serum from the third sample is diluted at a ratio of 1:2700. To carry out objective measurements that are comparable for all animals, the dilution of serum that gives a reading of 0.5 O.D. 4S0 above the highest reading of the pre-immune serum from the same animal has been conventionally termed "titer" . Figures la and lb show how the titer of the second and third samples are calculated for normal mice and for the NSE/hIL-6 transgenic mice, respectively. Figures 2a and 2b show the results of the experiment on immunisation using a mutant form o ~ f IL-6, Santl, of a typical normal mouse and of a typical NSE-hIL-6 transgenic mouse, respectively. In this case both the mice developed a large amount of anti-Santl antibodies. In fact, it is possible to detect a relatively strong signal even when the serum is diluted to 1:8100. Figures 2a and 2b show how the titers of the second and third samples are calculated for the normal mouse and for the transgenic mouse. Table 1 gives a summary of titer data (calculated as indicated above) for the second and third sample for all the mice innoculated during this " experiment. TABLE 1 IMMUNOGENICITY OF Sant 1 MICE GROUP SERUM TITER 2nd sample 3rd sample WT/wtIL-6 16 245 5150 17 1100 3900 18 1250 2600 19 430 1600 20 210 1800 Average 674 3010 NSE/wtIL-6 11 80 92 12 90 215 13 24 155 14 135 135 15 27 54 Average 71 130 Ratio of wt 9.5 23 mice titer/ NSE mice titer WT/Santl 6 150 270 7 1450 dead 8 2900 3600 9 1300 2700 10 3300 3800 Average 1820 2600 NSE/Santl 1 4000 4000 2 21.5 49 3 1750 >10000 4 1750 1150 5 2000 1800 Average 1900 3400 Ratio of wt 1 0.76 mice titer/ NSE mice titer As regards the mice innoculated with the wtIL-6 antigen, it can be seen that, apart from the variations between one animal and another, on average the non- transgenic mice developed an antibody response against wtIL-6 10-20 times stronger than that obtained in the NSE/IL-6 transgenic mice, this being proof of the fact that the transgenic mice have developed an immune tollerance of human hIL-6. On the contrary, as regards the mice innoculated with the antigen Sant 1, it can be seen that, once again apart from the variations between one animal and another, on average the non-transgenic mice developed an antibody response - equivalent to that obtained in NSE/hIL-6 transgenic mice, suggesting that the seven mutations, which when introduced into hIL-6 generated Santl, have also rendered the mutant Santl a completely foreign protein for an immune system that otherwise displays tollerance to hIL-6. EXAMPLE 2 The an ibodies developed in the serum of NSE/hTL-6 immunized with Santl are capable of recognising not only Santl. but also wild- vpe hTT,-6 This was to test whether or not the antibodies developed by mice against Santl were capable of recognising not only Santl itself, but also wild-type hIL-6 (wt hIL-6) . This hypothesis was tested once again using an ELISA test. After having verified the fact that antibodies developed in NSE/hIL-6 transgenic mice immunised with Santl are capable of recognising and binding the same mutant Santl immobilised on the bottom of ELISA plate wells, in a second experiment the wild- type IL-6 was bound in a non-covalent manner to the bottom of ELISA plate wells. After the phase in which the plastic of the wells is saturated with BSA, dilutions of serum from mice immunized with Santl were added to the wells to verify whether or not there was a presence of antibodies capable of recognising wtIL-6. For example, figure 3 shows the results of the experiment for the NSE/hIL-6 transgenic mouse. As can be seen, the antibody responses obtained for Santl and for wild-type IL-6 are extremely similar. In other words, it is possible to detect the presence of antibodies that have bound the wtIL-6 immobilised on the bottom of the wells in the serum of the third sample, even when the latter is diluted to a ratio of 1:8100. It should be noted that when the NSE/hIL-6 transgenic mice are immunised directly using wild-type IL-6, the antibody response directed at wild-type IL-6 itself is much lower: in effect it is not possible to detect anti-wtIL-6 antibodies in serum diluted to 1:8100 (see figure 1) . Other NSE/hIL-6 transgenic mice showed a response similar to that of the mouse illustrated in the example. E AMPLE 3 The antibodies developed in NSE/hTL-6 immunised with SaxLtl 3 ≤ also capable Of neutralising the biological activity of wild-type hIL-6 The object was to test whether or not these antibodies, developed in NSE/hIL-6 transgenic mice immunised with Santl, but capable of recognising wild- type IL-6, are also capable of neutralising the biological activitiy of wild-typ * e IL-6 itself. The biological activity of wild-type IL-6 under consideration was the ability to stimulate transcription by the C-reactive protein gene promoter in human Hep3B hepatoma cells. The effectiveness of stimulation of transcription was measured according to the state of the art (Gregory, B., Savino, R. and Ciliberto, G., J. Immunological Methods, 170, 47-56, 1994) . Human Hep3B hepatoma cells were stimulated with 4_ ng/ml of wild-type IL-6, in the presence of serial dilutions of the serum obtained in the third sample from two NSE/hIL-6 transgenic mice #4 and #5 (both immunised with Santl) . The results of the experiment are given in figure 4. It can be seen that both the serums diluted to 1:100 almost completely inhibit the biological activity of wild-type hIL-6 at 4 ng/ml on human hepatoma cells. At this point, investigations were carried out as to whether or not the occurance of this cross-reactive antibody response against wild-type hIL-6 was capable of altering the levels of wild-type hIL-6 measured in the serum of the NSE/hIL-6 transgenic mice immunized with Santl. The hIL-6 levels were measured according to the state of the art by means of a "sandwich" ELISA test, using a commercially available kit produced by the company "R&D Systems" , and scrupulously following the manufacturer's instructions. The levels of hIL-6 found both in the pre-immune sample and in the third sample were measured for four transgenic mice who had been immunized with Santl. The results are summarised in table 2. As can be seen, immunisation using Santl, as well as causing the appearance of a strong antibody response that recognises both Santl itself and the wtlL- 6, also causes an average decrease of over 500 times in the levels of hIL-6 that can be detected in the serum of the NSE/hIL-6 mice using the ELISA "sandwich" kit produced by R&D Systems. Table 2 - Decrease in the levels of hIL-6 that can be detected in the serum of NSE/hIL-6 mice hIL-6 levels in the serum Pre-immune serum 3rd sample Mouse No. 1 26 ng/ml 0.02 ng/ml Mouse No. 2 39 ng/ml 0.01 ng/ml Mouse No. 3 28 ng/ml 0.10 ng/ml Mouse No. 4 35 ng/ml- 0.10 ng/ml average 32 ng/ml 0.057 ng/ml EXAMPLE 4 The antibodies evelope in NSE/hTL-6 mice vaccinated with SanU ar≤ aϋ ≤ tΩ neutralize the biological activity of wild-type hIL-fi also i n vi vn It is well known that IL-6 induces the production of a series of proteins (called "acute phase proteins") by the liver. Serum Amyloid A, hereon referred as SAA, shows intense and rapid increase during acute events . The objective was to test whether or not these antibodies, developed in NSE/hIL-6 transgenic mice vaccinated with Santl, and capable of cross-reacting with wtIL-6, are also capable of neutralising the biological activity of wild type hIL-6 in vivo, measured as inhibition of the increase of mouse SAA (mSAA) following the injection of hIL-6. To this purpose, a blood sample (hereon referred as pre-injection sample) was taken from unimmunised (control) NSE/hIL-6 mice, from wt hIL-6 immunised and from Santl immunised NSE/hIL-6 mice. After the animals recovered from the bleeding, they were injected intra-peritoneally with 10 μg of wt hIL-6. Nine hours after the injection, a second blood sample (hereon referred as post-injection sample) was taken from both groups of animals . The mSAA levels were measured both in the pre-injection sample and in the post-injection sample according to the state of the art by means of a "sandwich" ELISA test, using a commercially available kit produced by the company "Biosource International", and scrupulously following the manufacturer's instructions. The results are summarised in Table 3. As can be seen, apart from the variations from between one animal and another, on average in unimmunized mice injection of 10 μg of hIL-6 determined a significant increase in the serum SAA levels, increase which was absent in the Santl vaccinated mice injected with the same amount of hIL-6. Therefore, vaccination with Santl, as well as causing the appearance of a strong antibody response that recognises both Santl itself and the wthIL-6 and that is able to neutralize wt hIL-6 biological activity in vi tro on human hepatoma cells, prevents in vivo the increase of mSAA levels induced by injection of hIL-6, in other words in neutralizes the biological activity of hIL-6 also in vivo . It should be noticed that immunization with wild type hIL-6, induces the production of a low amount of anti hIL-6 antibodies (see Example 1) , and this is not not able to prevent in vivo the increase of mSAA levels induced by injection of hIL-6, because mice immunized with wild type hIL-6 show an increase in the serum SAA levels comparable to the one observed in unimminised control mice. Table 3 - Increase in the levels of mSAA detectable in the serum of Santl-immunised and control NSE/hIL-6 transgenic mice after hIL-6 injection. mSAA levels in the serum mSAA levels fold increase Mice group mouse pre-inject. post :-inject. single group number sample sample mouse average 1 68 μg/ml - 24 μg/ml 0.35 San l 3 23 μg/ml 14 μg/ml 0.61 immunised 28 83 μg/ml 93 μg/ml 1.12 1.13 36 62 μg/ml 105 μg/ml 1.7 37 95 μg/ml 177 μg/ml 1.87 5 112 μg/ml 718 μg/ml 6.4 8 41 μg/ml 694 μg/ml 16.9 Control 14 140 μg/ml 613 μg/ml 4.4 9.01 unimmunised 21 47 μg/ml 479 μg/ml 10.13 22 51 μg/ml 412 μg/ml 8.1 51 53 μg/ml 433 μg/ml 8.15 11 72 μg/ml 784 μg/ml 10.3 wt hIL-6 12 54 μg/ml 380 μg/ml 6.9 8.9 immunised 13 28 μg/ml 310 μg/ml 11.1 15 16 μg/ml 117 μg/ml 7.2 EXAMPLE 5 Immunisation of NSEhIL-6 transgenic mice with hTT,-6 an santi formulated in a different. adjuvant, aluminum hydroxide It is well known that different antigens behaves differently when formulated in different adjuvants (Gupta, R. K. and Siber, G. R. , Vaccine, 13, 1263-1276, 1995) . The Complete (or Incomplete) Freund Adjuvant used in the immunization experiment described in the Example 1 cannot be used in humans because of side effects, mostly local reactions at the site of injection such as granuloma and cyst formation (Gupta, R. K. and Siber, G. R., Vaccine, 13, 1263-1276, 1995) . The objective was to determine whether a similar immune response, with high titer antibodies against Santl and also against wt hIL-6 could be raised in NSE/hIL-6 transgenic mice using an adjuvant commonly used for vaccination in humans. For this purpose, aluminun hydroxide was chosen, because it is today -the common adjuvant for human use, with an excellent track record of safety (Gupta, R. K. and Siber, G. R., Vaccine, 13, 1263-1276, 1995) . Groups of 8-10 NSE/hIL-6 transgenic mice (plus ten non-transgenic siblings born in the same litters used as controls) were immunized intraperitoneally with 100 μg of antigen (either Santl or wild type hIL-6) formulated in aluminum hydroxide at 1 mg/ml in a total volume of 100 μl (100 μg of aluminum hydroxide) for each injection, using an immunization protocol identical to the one described in the Example 1. The second blood sample (taken after the second injection or first booster) and the third blood sample (taken after the third injection or second booster) were then tested for the presence of antibodies against the antigen used for the immunization by means of the "ELISA" described in the Example 1. To carry out objective measurements that are comparable for all animals the dilution of serum that gives a reading of 0.5 O.D.450 above the highest reading of the preimmune serum from the same animal has been conventionally termed "titer" . The titer was measured as illustrated in figures la, lb, 2a and 2b for both normal and transgenic mice immunized with wild type hIL-6 and with Santl . The results are reported in Table 4. In general the amount of antibodies against the antigen obtained in this immunization experiment (titer) is higher as compared with the amount of antibodies obtained in the immunization experiment described in Example 1; indeed, it is part of the state of the art the fact that aluminum adjuvants are the adjuvants of choice for induction of serum antibodies (Gupta, R. K. and Siber, G. R., Vaccine, 13, 1263-1276, 1995) . More in particular, as regards the mice imunized with the wt hlL- 6 antigen, it can be seen again that (apart from the variation from one animal and another) on average the non-transgenic mice developed an antibody response against wt hIL-6 12-18 times stronger than that obtained in_ NSE/hIL-6 transgenic mice, this being proof of the fact that the transgenic mice have developed an immune tolerance to human IL-6 also when this antigen is injected formulated in aluminum hydroxide as adjuvant. On the contrary, as regards the mice immunized with Santl formulated in aluminum hydroxide, it can be seen that also in this case on average the non-transgenic mice developed an antibody response equivalent to that obtained in NSE/hIL-6 transgenic mice, as it was in the immunization experiment described in Example 1, suggesting that the seven mutations (which when introduced into hIL-6 generated Santl) have rendered the mutant a completely foreign protein also when formulated in aluminum hydroxide. Table 4. Immunogenicity of Santl and of wt hIL-6 formulated in aluminum hydroxide and injected intraperitoneally and NSE/hIL-6 transgenic and wild type control mice. mouse SERUM TITER Mice group number 2 nd sample 3 rd sample Non-transgenic 30 21960 11848 mice 32 6070 15790 immunised 34 7460 46000 with 46 14145 19600 wild type 49 6240 18600 hIL-6 in 54 1270 6960 aluminum 56 218 320 hydroxide 58 5470 5260 via 63 ■ 2138 2373 I.P. 65 1200 3810 Averages of the group 6617 13056 NSE/hIL-6 35 450 530 mice 51 2200 1630 immunised 53 169 100 with 60 160 630 wild type 75 55 217 hIL-6 in 85 81 1440 aluminum 87 110 176 hydroxide 90 64 390 via 93 1900 1700 I. P. 99 194 555 Averages of the group 538 737 20 7270 28185 Non-transgenic 21 7580 30200 mice 26 3555 54330 immunised 27 2185 10960 with 28 9060 35700 Santl in 29 7910 34515 aluminum 33 7380 43980 hydroxide 34 1160 10550 via I.P. 36 5785 19880 43 5035 23155 Averages of the group 5692 29145 NSE/hIL-6 22 4520 33105 mice 35 3516 28690 immunised 38 9990 44680 with 44 3580 14430 Santl in 46 1480 9940 aluminun 59 9780 20525 hydroxide 61 2360 63970 via I.P. 79 2250 26330 Averages of the group 4400 30210 EXAMPLE 6 Thp antibodies developed in the serum of NSE/hTL-6 mice vaccinated with s≤ntJ formulated in aluminum hydroxide are capable of recognising not only Santl but also wild-type hIL-6 This was to test whether the antibodies developed against Santl in NSE mice vaccinated with Santl formulated in aluminum hydroxide were capable of cross- reacting with wild type hIL-6 (wt hIL-6) . This was tested once again by "ELISA" using the same methodology described in the Example 2. The antibody titer was calculated as previously described and as illustrated in figures la, lb, 2a and 2b, and the data obtained are reported in Table 5. Table 5 - Cross-reactivity against wt hIL-6 of sera of NSE/hIL-6 transgenic mice vaccinated with Santl formulated in aluminum hydroxide and injected intraperitoneally. mouse 2 nα - sample serum titer 3 rc sample serum titer Mice group number wt hIL-6 Santl wt hIL-6 Santl NSE/hIL-6 22 2525 4520 31180 33105 mice 35 1925 3516 11860 28690 vaccinated 38 7065 9990 43850 44680 with 44 3580 3580 10585 14430 Santl in 46 1480 1480 8675 9940 aluminun 59 9990 9780 20360 20525 hydroxide 61 2800 2360 52000 63970 via I.P. 79 1980 2250 14890 26330 Averages of the group 3630 4400 22800 28750 Again, also when aluminum hydroxide is used as adjuvant for the immunization, the antibody titers against Santl and wild type hIL-6 are similar. Again, it should be noticed that when the NSE/hIL-6 transgenic mice are immunised with wild type hIL-6, the antibody response directed against wild type hIL-6 itself is much lower: for instance in the third blood sample the average titer against wt hIL-6 is 737 in the group of NSE/hIL-6 mice immunised with wt hIL-β (see Example 5) as compared with an average titer against wt hIL-6 of 22800 (13 times higher) in the group of NSE/hIL-6 mice vaccinated with Santl . KXAMPT.E 7 The antibodies developed in NSK/hTT,-6 mi e vaccinated with Santl formulated in aluminum hydroxide are also able to neutralise the biological activity of wild type hI -6 The objective was to test whether or not these antibodies, developed in NSE/hIL-6 transgenic mice vaccinated with Santl formulated in aluminum hydroxide, but capable of recognising wild type hIL-6, are also capable of neutralising the biological activity of wild type hIL-6 itself. The biological activity of wild-type IL-6 under consideration was the ability to stimulate transcription by the C-reactive gene promoter in human Hep3B hepatoma cells. The effectiveness of transcriptional stimulation was measured according to the state of the art (Gregory, B., Savino, R. and Ciliberto, G., J. Immimological Methods, 170, 47-56, 1994) . Human Hep3B hepatoma cells were stimulated with 4 ng/ml of wild-type hIL-6, and this extent of stimulation was taken as 100%, or with 4 ng/ml of wild type hIL-6 in the presence of serial dilutions of the serum obtained from the third blood sample from NSE/hIL-6 mice immunised with both Santl and wild type hIL-6; in the latter cases the extent of transcriptional stimulation was expressed as percent of the stimulation obtained in cells incubated with 4 ng/ml of wild type hIL-6 only. The results of the- experiment are given in Figures 5a and 5b. It can be seen that the serum of all mice diluted 1:400 almost completely inhibits the biological activity of wild type hIL-6 at 4 ng/ml on human hepatoma cells. Therefore, the ability to neutralize the bioactivity of exogenously added hIL-6 on human hepatoma cells was even higher for the sera of animals immunized with aluminum hydroxide than in the case of animals immunized with CFA (see Example 3 and compare Figure 5a with Figure 4) . When NSE/hIL-6 transgenic mice are immunised with wild type hIL-6 the very low amount of anti hIL-6 antibodies obtained is not sufficient to inhibit wild type hIL-6 biological activity on human hepatoma cells (see Figure 5b) . Also in this case, investigations were carried out as to whether or not the occurrance of this cross- reactive immune response against wild type hIL-6 was capable of altering the levels of wild type hIL-6 measured in the serum of NSE/hIL-6 transgenic mice immunised with both Santl and wild type hIL-6. The hIL-6 levels were measured as described in the Example 3 both in the pre-immune sample and in the third sample of both groups of mice. The results are summarised in Table 6. As can be seen, vaccination using Santl formulated in aluminum hydroxide, as well as causing the appearance of a strong antibody response that recognises both Santl itself and the wild type hIL-6, also causes an average decrease of about 1,400 times in the levels of hIL-6 that can be detected in the serum of the NSE/hIL-6 transgenic mice. Immunisation using wild type hIL-6 itself formulated in the same adjuvant causes only a- marginal decrease (3-fold as compared with 1,400-fold) in the levels of hIL-6 that can be detected in the serum. Table 6 - Decrease in the levels of hIL-6 that can be detected in the serum of NSE/hIL-6 mice immunised with Santl and wt hIL-6 formulated in aluminum hydroxide. mouse hIL-6 levels in the serum (pg/ml) Mice group number Pre-immune sample 3 rd sample NSE/hIL-6 35 27505 pg/ml 3522 pg/ml mice 51 24950 pg/ml 2662 pg/ml immunised 53 25817 pg/ml 4566 pg/ml with 60 23283 pg/ml 9810 pg/ml wild type 75 26373 pg/ml 8186 pg/ml hIL-6 in 85 23000 pg/ml 8959 pg/ml aluminum 87 25527 pg/ml 9172 pg/ml hydroxide 90 25590 pg/ml 20041 pg/ml via 93 23275 pg/ml 5834 pg/ml I.P. 99 30830 pg/ml 6582 pg/ml Averages of the group 25585 pg/ml 7933 pg/ml NSE/hIL-6 22 27300 pg/ml *9 pg/ml mice 35 31778 pg/ml *9 pg/ml immunised 38 25223 pg/ml *9 pg/ml with 44 29385 pg/ml 41 pg/ml Santl in 46 20600 pg/ml *9 pg/ml aluminum 59 22820 pg/ml 45 pg/ml hydroxide 61 23125 pg/ml *9 pg/ml via I.P. 79 24510 pg/ml *9 pg/ml Averages of the group 25593 pg/ml 18 pg/ml The star (*) indicates the lower limit of sensitivity of the assay. EXAMPLE 8 Hie antibodies developed in NSE/hττ,-6 mic vaccinated with £ jUt formulated in aluminum hydroxide are able to neutralize the biological activity of wt h L- 6 al o in vi vo The objective was to test whether or not these antibodies, developed in NSE/hIL-6 transgenic mice vaccinated with Santl formulated in aluminum hydroxide, but capable of recognising wtIL-6, are also capable of neutralising the biological activity of wild type hIL-6 in vivo, measured as the increase of mouse SAA (mSAA) serum levels induced in the mice by injection of hIL-6, as described in the Example 4. The experiment was performed as described in the Example 4 on unimmunised (control) NSE/hIL-6 mice and on NSE/hIL-6 mice immunized with Santl formulated in aluminum hydroxide. The results are summarised in Table 7. As can be seen, apart from the variations from between one animal and another, on average again in unimmunized mice injection of 10 μg of hIL-6 determined a 5- to 6-fold increase in the serum SAA levels . No increase was obtained in the mice vaccinated with Santl formulated in aluminum hydroxide, injected with the same amount of hIL-6. Table 7 - Increase in the levels of mSAA detectable in the serum of Santl-vaccinated and control NSE/hIL-6 transgenic mice after hIL-6 injection. mSAA levels in the serum mSAA levels fold increase Mice group mouse pre-m-ject . post - m-ject. single group number sample sample mouse average 22 6.1 μg/ml 7.1 μg/ml 1.14 35 4.4 μg/ml 5.5 μg/ml 1.24 38 7.4 μg/ml 9.9 μg/ml 1.34 Santl 44 4.6 μg/ml 6.5 μg/ml 1.4 1.19 vaccinated 46 5.2 μg/ml 6.9 μg/ml 1.33 59 6.7 μg/ml 7.5 μg/ml 1.13 61 8.6 μg/ml 10.2 μg/ml 1.19 79 8.8 μg/ml 6.8 μg/ml 0.77 15 85 μg/ml 265 μg/ml 3.1 16 99 μg/ml 366 μg/ml 3.7 19 296 μg/ml 2997 μg/ml 10.1 Control 20 41 μg/ml 146 μg/ml 3.6 5.41 unimmunised .21 bis 45 μg/ml 276 μg/ml 6.1 55 41 μg/ml 303 μg/ml 7.4 56 75 μg/ml 291 μg/ml 3.9 Therefore, vaccination with Santl, as well as causing the appearance of a strong antibody response that recognises both Santl itself and the wthIL-6 and that is able to neutralize wt hIL-6 biological activity in vitro on human hepatoma cells, prevents in vivo the increase of mSAA levels induced by injection of hIL-6, in other words in neutralizes the biological activity of hIL-6 also in vivo. EXAMPLE 9 Vaccination of NSEhIL-6 transgenic mice with hIL-6 and Santl formulated in aluminum hydroxide v a intradermal administra ion route Examples 5, 6, 7 and 8 above show that it is possible to obtain in animals otherwise tolerant to wt hIL-6 a strong antibody response against wt hIL-6 itself, that is able to neutralize hIL-6 bioactivity both in vi tro and in vivo, by using a mutant form of hIL-6 (Santl) formulated in an adjuvant (aluminum hydroxide) compatible with human use. However, in the immunisation experiment described in the Example 5, the antigen was injected intraperitoneally, which is not an administration route commonly used for immunization in humans. The objective was to determine whether a similar immune response, with high titer antibodies against Santl and also against wt hIL-6 could be raised in NSE/hIL-6 transgenic mice using an administration route used for vaccination in humans. Groups of 8-9 NSE/hIL-6 transgenic mice (plus ten non-transgenic siblings born in the same litters used as controls) were immunised intradermally (I.D.), an administration route in mouse which correspond to the sub-cutaneous (S.C.) administration route in humans, currently used for the administration of several vaccines as decribed in the state of the art. Again, 100 μg of antigen (either Santl or wild type hIL-6) formulated in aluminum hydroxide at 1 mg/ml in a total volume of 100 μl (100 μg of aluminum hydroxide) were used for each injection, using an immunization protocol identical to the one described in the Example 1. The second blood sample (taken after the second injection or first booster) and the third blood sample (taken after the third injection or second booster) were then tested for the presence of antibodies against the antigen used for the immunization by means of an "ELISA" method identical to the one already described in the Example 1. To carry out objective measurements that are comparable for all animals the dilution of serum that gives a reading of 0.5 O.D.450 above the highest reading of the preimmune serum from the same animal has been conventionally termed "titer" . The titer was measured as illustrated in figures la, lb, 2a and 2b for both normal and transgenic mice immunized with wild type hIL-6 and with Santl. The results are reported in Table 8. Again, as regards the mice imunized with the wt hlL- 6 antigen, it can be seen again that (apart from the variation from one animal and another) on average the non-transgenic mice developed an antibody response against wt hIL-6 40-50 times stronger than that obtained in NSE/hIL-6 transgenic mice, this being proof of the fact that the transgenic mice have developed an immune tolerance to human IL-6 also when this antigen is injected formulated in aluminum hydroxide via intra- dermal administration route. On the contrary, as regards the mice immunized with Santl formulated in aluminum hydroxide, it can be seen that also in this case on average the non-transgenic mice developed an antibody response equivalent to that obtained in NSE/hIL-6 transgenic mice, as it was in the immunization experiments described in Examples 1 and 5, suggesting that the seven substitutions (which when introduced into hIL-6 generated Santl) have rendered the mutant a completely foreign protein also when formulated in aluminum hydroxide and injected via intradermal administration route. Table 8. Immunogenicity of Santl and of wt hIL-6 formulated in aluminum hydroxide and injected intradermally (I.D.) and NSE/hIL-6 transgenic and wild type control mice. mouse SERUM TITER Mice group number 2 nd : 3 rd sample Non-transgenic 31 6220 4250 mice 45 888 1270 immunised 48 52 1150 with 50 1060 7640 wild type 55 4050 4560 hIL-6 in 57 4337 9260 aluminum 61 4065 9020 hydroxide 64 13690 20000 via 66 5460 7500 I.D. 65 680 700 Averages of the group 4050 6535 NSE/hIL-6 47 240 195 mice 52 51 25 immunised 62 30 120 with 81 39 160 wt hIL-6 86 97 200 in aluminum 91 77 100 hydroxide 96 306 210 via I.D. 2 25 100 Averages of the group 108 139 25 890 4610 Non-transgenic 30 540 3670 mice 31 4370 13960 immunised 32 1770 10690 with 37 7860 13235 Santl in 39 8400 26680 aluminum 40 7360 49774 hydroxide 45 6510 4770 via I.D. 50 1000 16280 53 470 3100 Averages of the group 3920 14680 41 4640 5735 NSE/hIL-6 42 2145 7640 mice 47 1150 4490 immunised 48 1600 8700 with 49 2110 6740 Santl in 51 8980 20250 aluminum 52 11400 23380 hydroxide 56 2030 9880 via I.D. 65 4290 14080 Averages of the group 4260 11210 EXAMPLE 10 The antibodies developed in the serum of NSE/hTL-6 mice vaccinated with. Santl formulated n l um hydroxide are capable of recognising not only Santl but also wild-type hIL-6 This was to test whether or not the antibodies developed in NSE mice vaccinated with Santl formulated in aluminum hydroxide and injected via intradermal administration route were capable of cross-reacting with wild type hIL-6 (wt hIL-6) . This was tested once again by "ELISA" using the same methodology described in the Example 2. The antibody titer was calculated as previously described and as illustrated in figures la, lb, 2a and 2b, and the data obtained are reported in Table 9 . Table 9 - Cross-reactivity against wt hIL-6 of sera of NSE/hIL-6 transgenic mice vaccinated with Santl formulated in aluminum hydroxide and injected intradermally. mouse 2 nd sample serum titer 3 rd sample serum titer Mice group number wt hIL-6 Santl wt hIL-6 Santl 41 960 4640 5800 5735 NSE/hIL- 6 42 2720 2145 7820 7640 mice 47 665 1150 2190 4490 vaccinated 48 1010 1600 7075 8700 with 49 2660 2110 5060 6740 Santl in 51 6660 8980 17970 20250 aluminun 52 13380 11400 20740 23380 hydroxide 56 2360 2030 7240 9880 via I . D . 65 4290 4290 10700 14080 Averages of the group 385 4260 9400 11210 Again, also when aluminum hydroxide is used as adjuvant for the immunization this time via intradermal administration route, the antibody titers against Santl and wild type hIL-6 are extremely similar. Once more, it should be noticed that when the NSE/hIL-6 transgenic mice are immunised with wild type hIL-6, the antibody response directed against wild type hIL-6 itself is much lower: for instance in the third blood sample the average titer against wt hIL-6 is 139 in the group of NSE/hIL-6 mice immunised with wt hIL-6 (see Example 9) as compared with an average titer against wt hIL-6 of 9400 (70 times higher) in the group of NSE/hIL-6 mice immunised with Santl . EXAMPLE 11 JT±L≤ antibodies developed in NSE/hτL-6 ice accin t d With Santl formulated in aluminum hydroxide and injected intradermally are also able to neutralise the biological activity of wild type hTL-6 The objective was to test whether or not these antibodies, developed in NSE/hIL-6 transgenic mice vaccinated with Santl formulated in aluminum hydroxide and injected intradermally, are also capable of neutralising the biological activity of wild type hIL-6 itself. Again, the biological activity of wild-type IL-6 under consideration was the ability to stimulate transcription by the C-reactive gene promoter in human Hep3B hepatoma cells. The effectiveness of transcriptional stimulation was measured according to the state of the art (Gregory, B., Savino, R. and Ciliberto, G., J. Immunological Methods, 170, 47-56, 1994) . As it was in the Example 7, human Hep3B hepatoma cells were stimulated with 4 ng/ml of wild-type hIL-6, and this extent of stimulation was taken as 100%, or with 4 ng/ml of wild type hIL-6 in the presence of serial dilutions of the serum obtained from the third blood sample from NSE/hIL-6 mice immunised intradermally with both Santl and wild type hIL-6; in the letter cases the extent of transcriptional stimulation was expressed as percent of the stimulation obtained in cells incubated with 4 ng/ml of wild type hIL-6 only. The results of the experiment are given in Figures 6a and 6b. It can be seen that the serum of all mice diluted 1:400 inhibits more than 80% of the biological activity of wild type hIL-6 at 4 ng/ml on human hepatoma cells. Again, it should be noticed that when NSE/hIL-6 transgenic mice are immunised with wild type hIL-6 the very low amount of anti hIL-6 antibodies obtained is not sufficient to inhibit wild type hIL-6 biological activity on human hepatoma cells (see Figure 6b) . Also in this case, investigations were carried out as to whether or not the occurrance of this cross- reactive immune response against wild type hIL-6 was capable of altering the levels of wild type hIL-6 measured in the serum of NSE/hIL-6 transgenic mice immunised with both Santl and wild type hIL-6. The hIL-6 levels were measured as described in the Example 3 both in the pre-immune sample and in the third sample of both groups of mice. The results are summarised in Table 10. As can be seen, vaccination using Santl formulated in aluminum hydroxide and injected intradermally, as well as causing the appearance of a strong antibody response that recognises both Santl itself and the wild type hIL-6, also causes an average decrease of about 350 times in the levels of hIL-6 that can be detected in the serum of the NSE/hIL-6 transgenic mice. On the contrary, immunisation using wild type hIL-6 itself formulated in the same adjuvant causes only a marginal decrease (2.4-fold as compared with 350-fold) in the levels of hIL-6 that can be detected in the serum. Table 10 - Decrease in the levels of hIL-6 that can be detected in the serum of NSE/hIL-6 mice immunised with Santl and wt hIL-6 formulated in aluminum hydroxide and injected intradermally. mouse IL-6 Je els m the serum (pg/ml) Mice group number Pre-immune sample 3 rd sample NSE/hIL-6 47 23790 pg/ml 5684 pg/ml mice 52 25450 pg/ml 3110 pg/ml immunised 62 26190 pg/ml 4490 pg/ml with 81 24690 pg/ml 25930 pg/ml wt hIL-6 86 22890 pg/ml 8600 pg/ml in aluminum 91 16600 pg/ml 6884 pg/ml hydroxide 96 16760 pg/ml 5800 pg/ml via I.D. 2 22970 pg/ml 14670 g/ml Averages of the group 22418 pg/ml 9396 pg/ml NSE/hIL-6 41 21640 pg/ml *9 pg/ml mice 42 19040 pg/ml *9 pg/ml immunised 47 22940 pg/ml 173 pg/ml with 48 23990 pg/ml *9 pg/ml Santl in 49 21640 pg/ml 79 pg/ml aluminun 51 25680 pg/ml 21 pg/ml hydroxide 52 24410 pg/ml 17 pg/ml via I.D. 56 26540 pg/ml 204 pg/ml 65 20410 pg/ml 78 pg/ml Averages of the group 22920 pg/ml 66 pg/ml The star (*) indicates the lower limit of sensitivity of the assay. EXAMPLE 12 The. antibodies developed in MSE/hTT,-6 mice vaccinated with Santl formulated in aluminum hydroxide ≤ϋ injected intradermally are able to neutralize tJaa biological activity of wt hII,-6 also in vi vo The objective was to test whether or not these antibodies, developed in NSE/hIL-6 transgenic mice vaccinated with Santl formulated in aluminum hydroxide and injected intradermally, are also capable of neutralising one of the biological activities of wild type hIL-6 in vivo, that is the increase of mouse SAA (mSAA) levels normally induced in the mice by injection of hIL-6, as described in the Example 4. The experiment was performed as described in the Example 4 on NSE/hIL-6 mice vaccinated with Santl formulated in aluminum hydroxide and injected intradermally. The values obtained have been compared with the control unimmunised mice of the experiments described in the Examples 4 (Table 3) and 8 (Table 7) . The results are summarised in Table 11. As can be seen, apart from the variations from between one animal and another, on average again the 7-fold increase in SAA levels caused by hIL-6 injection in unimmumnised mice was absent in the mice vaccinated with Santl formulated in aluminum hydroxide injected intradermally. Table 11 - Increase in the levels of mSAA detectable in the serum of Santl-immunised and control NSE/hIL-6 transgenic mice after hIL-6 injection. mSAA levels in the serum mSAA levels fold increase Mice group mouse pre-inject. post-inject. single group number sample sample mouse average 41 49 μg/ml 20 μg/ml 0.46 42 10 μg/ml 9 μg/ml 0.9 47 64 μg/ml 56 μg/ml 0.87 Santl 48 31 μg/ml 18 μg/ml 0.74 vaccinated 49 8 μg/ml 18 μg/ml 2.2 1.22 51 23 μg/ml 23 μg/ml 1.0 52 23 μg/ml 40 μg/ml 1.7 56 39 μg/ml 41 μg/ml 1.05 65 31 μg/ml 66 μg/ml 2.1 5 112 μg/ml 718 μg/ml 6.4 8 41 μg/ml 694 μg/ml 16.9 14 140 μg/ml 613 μg/ml 4.4 15 85 μg/ml 265 μg/ml 3.1 16 99 μg/ml 366 μg/ml 3.7 19 296 μg/ml 2997 μg/ml 10.1 Control 20 41 μg/ml 146 μg/ml 3.6 7.07 unimmunised 21 47 μg/ml 479 μg/ml 10.13 21 bis 45 μg/ml 276 μg/ml 6.1 22 51 μg/ml 412 μg/ml 8.1 51 53 μg/ml 433 μg/ml 8.15 55 41 μg/ml 303 μg/ml 7 . 4 56 75 μg/ml 291 μg/ml 3 . 9 Therefore, vaccination with Santl performed with an adjuvant and an administration route compatible with use in humans, as well as causing the appearance of a strong antibody response that recognises both Santl itself and the wthIL-6 and that is able to neutralize wt hIL-6 biological activity in vi tro on human hepatoma cells, prevents in vivo the increase of mSAA levels induced by injection of hIL-6, in other words in neutralizes the biological activity of hIL-6 also in vivo.

Claims: Ci IMS 1. Use of muteins of a wild-type cytokine, that are also receptor antagonists of that cytokine, as immunogens for the preparation of pharmaceutical compositions for the treatment or prevention of diseases caused by over¬ production of that specific wild-type cytokine. 2. Use of muteins of a wild-type cytokine according to claim 1, in which the wild-type cytokine is human interleukin 6. 3. Use of muteins of human interleukin 6 according to claim 2 for the treatment or prevention of diseases caused by over-production of that wild-type cytokine, such as chronic auto-immune disorders, systemic lupus erythematosus, myeloma/plasmacytoma, post-menopausal osteoporosis and cancer cachexy. 4. Pharmaceutical compounds for the treatment or prevention of diseases caused by over-production of a wild-type cytokine, characterised by the fact that they contain as an active principle at least one mutein of that wild-type cytokine in a pharmacologically effective amount . 5. Pharmaceutical preparations according to claim 4, containing diluents, excipients or pharmaceutical vehicles, suitably selected and dosed bearing in mind the form of administration that is required. 6. Vaccines according to claim 4 for immunization against a wild-type cytokine, ' the over-production of which causes diseases, containing as an active principle at least one mutein of that cytokine, in a pharmaceutically effective amount in dilutants, excipients or pharmaceutically acceptable vehicles. 7. Vaccines according to claim 6, for immunization against human interleukin 6, the over-production of which causes diseases such as chronic auto-immune disorders, systemic lupus erythematosus, myeloma/plasmacytoma, post- menopausal osteoporosis and cancer cachexy. 8. Vaccines according to claim 7, containing as active principle the mutein of human interleukin 6 (hlL- 6) , denominated Santl, containing the mutations Tyr 31 Asp, Gly 35 Phe, Ser 118 Arg, Val 121 Asp, Gin 175 Ile, Ser 176 Arg, Gin 183 Ala. 9. Vaccines according to claim 8, containing as active principle the mutein Santl formulated in aluminum hydroxide at 1 mg/ml, to be injected three times sub¬ cutaneously in the amount of 0.1-100 μg of mutein per injection. 10. Vaccines according to claim 7, containing as active principle any version of hIL-6 containing aminoacid substitutions capable of making it an hIL-6 receptor antagonist.

Inventors: CILIBERTO GENNARO, CORTESE RICCARDO, SAVINO ROCCO, CILIBERTO, GENNARO, CORTESE, RICCARDO, SAVINO, ROCCO
Applicants: ANGELETTI P IST RICHERCHE BIO, CILIBERTO GENNARO, CORTESE RICCARDO, SAVINO ROCCO, CILIBERTO, GENNARO, CORTESE, RICCARDO, ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANG, SAVINO, ROCCO
Application year: 1996
Main classification: A61K39
IPC codes: A61K38, A61K39, A61P37, A61P43, C12N15